Adjusting for treatment switching in randomised controlled trials

Thursday 8 February 2018, 2.00PM to 3.15pm

Speaker(s): Nicholas Latimer, ScHARR, University of Sheffield

Abstract: Estimates of the overall survival benefit of new cancer treatments are often confounded by treatment switching in randomised controlled trials (RCTs). For Health Technology Assessment (HTA) estimates of the unconfounded overall survival benefit associated with new treatments are needed. Several switching adjustment methods have been advocated in the literature, some of which have been used in HTA, but all make strong assumptions that are not possible to test perfectly. In addition, each of these methods can be applied in a multitude of ways and seemingly innocuous choices around how a particular method is applied can importantly affect the results they produce. In this talk I will introduce the adjustment methods and will focus on key application decisions to watch out for when undertaking or assessing adjustment analyses.

Location: ARRC Auditorium A/RC/014

Adjusting for treatment switching in randomised controlled trials from cheweb1

Who to contact

For more information on these seminars, contact:

Maria Jose Aragon
mariajose.aragonaragon@york.ac.uk
Jessica Ochalek
jessica.ochalek@york.ac.uk

CHE Seminar Programme

  • Monday 21 January
    Professor Rachel Baker, Yunus Centre for Social Business and Health
  • Thursday 7 February
    Professor Philip Clarke, The Universities of Melbourne and Oxford
  • Thursday 7 March
    Professor Sonia Bhalhotra, University of Essex 
  • Thursday 4 April 
    Eugenio Zucchelli, Lancaster University
  • Thursday 2 May
    Davide Rasella, Fiocruz Brazil
  • Thursday 4 July
    Stephanie von Hinke Kessler Scholder, Bristol University
  • Thursday 5 September
    Jose-Luis Fernandez, LSE 
  • Thursday 3 October
    Soren Rud Kristensen, Imperial
  • Thursday 7 November
    Linda Davies, Manchester University
  • Wednesday 5 December
    Mandy Ryan, HERU, University of Aberdeen